Summary
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.
Moderna’s stock doubles on promising cancer-vaccine results
Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at MarketWatch →
